Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates.

Alcohol misuse is the second most common indication for liver transplantation in the United States. Our post-transplant alcoholism treatment trial suggested that current interventions might not be transferable to liver transplantees. We sought to identify differences between patients awaiting liver transplantation and alcoholics entering treatment without severe liver disease. Thirty transplant patients were compared to thirty naltrexone study patients on medical status, alcohol and drug use, alcohol craving, motivation for treatment, psychiatric symptoms, and psychosocial problems. Lifetime alcohol consumption was greater for transplant patients compared to naltrexone patients. In contrast to the naltrexone group, transplant patients denied craving for alcohol and showed little motivation for alcoholism treatment. Groups did not differ on other psychosocial measures. Liver transplant patients differ from patients in alcoholism treatment trials on measures of alcohol consumption, alcohol craving and motivation for treatment. Alcoholism interventions should accommodate their medical condition and boost motivation for continued abstinence.

A pilot test of motivational interviewing groups for dually diagnosed inpatients.

Motivational interviewing is a brief treatment approach designed to produce rapid, internally motivated change in addictive behaviors. Motivational interviewing shows promise for engaging clients with dual psychiatric and psychoactive substance use diagnoses in treatment. While initially developed as an individual treatment approach, key motivational enhancement principles may be applied to structured group interventions to facilitate its introduction to inpatient dual-diagnosis treatment. We describe how we developed and pilot-tested a motivational interviewing group for dually diagnosed inpatients, and illustrate successes and pitfalls in clinical implementation. Group participants were readily engaged by the entertaining format and often provocative content, and appeared to benefit from exploration of their ambivalence regarding change. Directions for further development and evaluation are proposed.

Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed.

Alcoholic liver disease is the second most common indication for liver transplantation in the United States. The lack of alcoholism treatment studies led us to study motivational enhancement therapy (MET) plus naltrexone after transplant. The authors could not complete this study. Sixty alcoholic patients were to receive MET plus naltrexone or placebo for 6 months. Fifty men and 5 women were screened. Nine died and 15 were not approached. Of 31 approached, 20 were ineligible, 11 refused, and 5 entered but dropped out before completion. Barriers to posttransplant alcoholism included infirmity, intensive medical management, and denial for alcoholism treatment. Because 30%-50% of alcoholic patients drink after transplant, the authors suggest using MET alone pretransplant.

Interpreting the significance of drinking by alcohol-dependent liver transplant patients: fostering candor is the key to recovery.

Few studies have examined the value of treating alcohol addiction either before or after liver transplantation. Nevertheless, most liver transplant programs and many insurance companies require 6 months to 1 year of abstinence from alcohol as a condition of eligibility for liver transplantation (the 6-month rule). We believe there are potentially harsh clinical consequences to the implementation of this rule. For example, the natural history of alcohol use disorders often involves brief fallbacks to drinking ("slips"), but when alcoholic liver transplant candidates slip, most are removed from consideration for transplantation or are required to accrue another 6 months of sobriety. Because there is no alternative treatment to liver transplantation for most patients with end-stage liver disease, the 6-month rule could be lethal in some circumstances. In this review, we survey the literature concerning the ability of the 6-month rule to predict drinking by alcoholic patients who undergo liver transplantation and examine its impact on the health consequences of drinking before and after liver transplantation. We believe that fostering candor between the alcoholic patient and the transplant team is the key to recovery from alcoholism. We conclude that it is unethical to force alcoholic liver patients who have resumed alcohol use while waiting for or after transplantation to choose between hiding their drinking to remain suitable candidates for transplantation or risk death by asking for treatment of alcoholism. Consequently, we advocate a flexible approach to clinical decision making for the transplant professional caring for an alcoholic patient who has resumed drinking and provide specific guidelines for patient management.

Substance-use situations and abstinence predictions in substance abusers with and without personality disorders.

Rates of personality disorders (PDs) in substance abusers are higher than in the general population. Comorbid PDs are believed to complicate the treatment of addicted patients: in addition to having more severe substance-use disorders and life problems, personality-disordered patients may use substances differently than their peers without Axis II diagnoses. In a sample of 339 adults receiving inpatient treatment for alcohol or drug abuse/dependence, 71.7% received Axis II diagnoses, and they presented a more severe clinical picture. They also had more self-reported "impulsive" substance use and use of drugs or alcohol in positive situations. Different groups of personality-disordered patients had different patterns of self-efficacy for abstinence for hypothetical future situations.

Identifying young adult substance abusers: the Rutgers Collegiate Substance Abuse Screening Test.

Substance abuse is a serious problem in the young adult population, yet there exists a lack of reliable screening measures for use in identifying problem users in this age group. The Rutgers Collegiate Substance Abuse Screening Test (RCSAST) is a 25-item, true/false questionnaire that was created to provide a reliable means of identifying young adult substance abusers. Three groups completed the RCSAST: a clinical sample of 84 young adult, problem substance users; a group of 33 young adults who were referred to an assistance program but were judged not to have a substance use problem; and a control sample of 87 young adult, nonproblem substance users. The RCSAST correctly classified 94% of the clinical subjects as problem users, and 89% of the control subjects as nonproblem users. The difference between the average total scores for the two groups was highly significant. In addition, the RCSAST was able to distinguish between problem and nonproblem users within the sample of subjects who were referred for evaluation. The findings support the use of the RCSAST in identifying young adult substance abusers.